# Lapatinib + Vinorelbine in ErbB2 Overexpressing, First or Second Line Metastatic Breast Cancer Subjects

> **NCT00709618** · PHASE2 · TERMINATED · sponsor: **GlaxoSmithKline** · enrollment: 44 (actual)

## Conditions studied

- Neoplasms, Breast

## Interventions

- **DRUG:** Lapatinib, Vinorelbine

## Key facts

- **NCT ID:** NCT00709618
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-06
- **Primary completion:** 2012-05
- **Final completion:** 2012-05
- **Target enrollment:** 44 (ACTUAL)
- **Why stopped:** Evolving standard of care practices in this disease setting was limiting enrolment and leading to a delay in delivering this study information to the public.
- **Last updated:** 2014-07-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00709618

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00709618, "Lapatinib + Vinorelbine in ErbB2 Overexpressing, First or Second Line Metastatic Breast Cancer Subjects". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00709618. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*